<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8806605</journal-id>
<journal-id journal-id-type="pubmed-jr-id">6644</journal-id>
<journal-id journal-id-type="nlm-ta">Mod Pathol</journal-id>
<journal-id journal-id-type="iso-abbrev">Mod. Pathol.</journal-id>
<journal-title-group>
<journal-title>Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc</journal-title>
</journal-title-group>
<issn pub-type="ppub">0893-3952</issn>
<issn pub-type="epub">1530-0285</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27443514</article-id>
<article-id pub-id-type="pmc">5541389</article-id>
<article-id pub-id-type="doi">10.1038/modpathol.2016.135</article-id>
<article-id pub-id-type="manuscript">NIHMS882374</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Germline multi-gene hereditary cancer panel testing in an unselected endometrial cancer cohort</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ring</surname>
<given-names>Kari L.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bruegl</surname>
<given-names>Amanda S.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Allen</surname>
<given-names>Brian A.</given-names>
</name>
<degrees>MS</degrees>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Elkin</surname>
<given-names>Eric P.</given-names>
</name>
<degrees>MPH</degrees>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Singh</surname>
<given-names>Nanda</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hartman</surname>
<given-names>Anne-Renee</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Daniels</surname>
<given-names>Molly S.</given-names>
</name>
<degrees>MS, CGC</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Broaddus</surname>
<given-names>Russell R.</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Gynecologic Oncology and Reproductive Medicine</aff>
<aff id="A2">
<label>2</label>Oregon Health &amp; Science University, Portland, OR, Department of Obstetrics and Gynecology</aff>
<aff id="A3">
<label>3</label>Myriad Genetics, Inc., Salt Lake City, UT</aff>
<aff id="A4">
<label>4</label>The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Pathology</aff>
<author-notes>
<corresp id="FN1">Corresponding Author: Russell R. Broaddus, M.D. Ph.D., Department of Pathology, Unit 85, 1515 Holcombe Blvd, Houston, TX 77030, (T): 713-745-2794, (F): 713-792-5532, <email>rbroaddus@mdanderson.org</email></corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>20</day>
<month>6</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>22</day>
<month>7</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<month>11</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>11</month>
<year>2017</year>
</pub-date>
<volume>29</volume>
<issue>11</issue>
<fpage>1381</fpage>
<lpage>1389</lpage>
<!--elocation-id from pubmed: 10.1038/modpathol.2016.135-->
<abstract>
<p id="P1">Hereditary endometrial carcinoma is associated with germline mutations in Lynch syndrome genes. The role of other cancer predisposition genes is unclear. We aimed to determine the prevalence of cancer predisposition gene mutations in an unselected endometrial carcinoma patient cohort. Mutations in 25 genes were identified using a next generation sequencing based panel applied in 381 endometrial carcinoma patients who had undergone tumor testing to screen for Lynch syndrome. Thirty five patients (9.2%) had a deleterious mutation: 22 (5.8%) in Lynch syndrome genes (3 <italic>MLH1</italic>, 5 <italic>MSH</italic>2, 2 <italic>EPCAM-MSH2</italic>, 6 <italic>MSH6</italic>, 6 <italic>PMS2</italic>) and 13 (3.4%) in 10 non-Lynch syndrome genes (4 <italic>CHEK2</italic>, 1 each in <italic>APC</italic>, <italic>ATM</italic>, <italic>BARD1</italic>, <italic>BRCA1</italic>, <italic>BRCA2</italic>, <italic>BRIP1</italic>, <italic>NBN</italic>, <italic>PTEN</italic>, <italic>RAD51C</italic>). Of 21 patients with deleterious mutations in Lynch syndrome genes with tumor testing, 2 (9.5%) had tumor testing results suggestive of sporadic cancer. Of 12 patients with deleterious mutations in <italic>MSH6</italic> and <italic>PMS2</italic>, 10 were diagnosed at age &gt;50 and 8 did not have a family history of Lynch syndrome associated cancers. Patients with deleterious mutations in non-Lynch syndrome genes were more likely to have serous tumor histology (23.1% v 6.4%, p=0.02). The 3 patients with non-Lynch syndrome deleterious mutations and serous histology had mutations in <italic>BRCA2</italic>, <italic>BRIP1</italic>, and R<italic>AD51C</italic>. Current clinical criteria fail to identify a portion of actionable mutations in Lynch syndrome and other hereditary cancer syndromes. Performance characteristics of tumor testing are sufficiently robust to implement universal tumor testing to identify patients with Lynch syndrome. Germline multi-gene panel testing is feasible and informative, leading to the identification of additional actionable mutations.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>